Antofloxacin-based Bismuth Quadruple Therapy for Helicobacter pylori Eradication
10.3969/j.issn.1008-7125.2021.02.002
- Author:
Wulian LIN
1
;
Xiaojian HE
1
;
Haitao LI
1
;
Zhijian ZHANG
1
;
Guanpo ZHANG
1
;
Dazhou LI
1
;
Wen WANG
1
Author Information
1. Department of Gastroenterology, the 900th Hospital of Joint Logistics Support Force, PLA, Oriental Hospital Affiliated to Xiamen University, Fuzhou General Clinical Medical College, Fujian Medical University
- Publication Type:Journal Article
- Keywords:
Antofloxacin;
Bismuth Quadruple Therapy;
Helicobacter pylori;
Levofloxacin;
Quinolones;
Safety;
Treatment Outcome
- From:
Chinese Journal of Gastroenterology
2021;26(2):71-75
- CountryChina
- Language:Chinese
-
Abstract:
Background: Resistance to antibiotics is the major cause for failure of Helicobacter pylori (Hp) eradication therapy. Therefore, exploring new eradication regimen has become a hotspot of research. Aims: To investigate the efficacy, safety and optimal dose of antofloxacin-based bismuth quadruple therapy for first-line Hp eradication. Methods: Four hundred patients with Hp infection and naive to eradication therapy were prospectively recruited from January 2019 to December 2019 at the 900th Hospital of Joint Logistics Support Force, PLA and were randomly divided into four groups: low-, normal-, and high-dose antofloxacin groups and control group, 100 cases in each group. Patients in low-, normal-, and high-dose antofloxacin groups received antofloxacin 100 mg, 200 mg, and 300 mg qd, respectively, pantoprazole 40 mg bid, bismuth potassium citrate 220 mg bid, and amoxicillin 1 000 mg bid for 14 days; patients in control group received levofloxacin 500 mg qd and the other three drugs with same dose and frequency for 14 days. Adverse events during treatment were recorded. Hp eradication was confirmed by
